Gene therapy for prostate cancer

被引：2
作者：
Gingrich J.R. [1 ]
Chauhan R.D. [1 ]
Steiner M.S. [1 ]
机构：
[1] Department of Urology, University of Tennessee Medical Center, 956 Court Avenue, H216, Memphis, 38163, TN
来源：
Current Oncology Reports | 2001年 / 3卷 / 5期
关键词：
Cytosine Deaminase; Gene Therapy; Herpes Simplex Virus Thymidine Kinase; Prostate Cancer; Radical Prostatectomy;
D O I：
10.1007/s11912-001-0031-6
中图分类号：
学科分类号：
摘要：
Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed. © 2001, Current Science Inc.
引用
收藏
页码：438 / 447
页数：9
相关论文
共 58 条
[1]  
Vile R.G., Russell S.J., Lemoine N.R., Cancer gene therapy: hard lessons and new courses, Gene Ther, 7, pp. 2-8, (2000)
[2]  
Monahan P.E., Samulski R.J., AAV vectors: is clinical success on the horizon?, Gene Ther, 7, pp. 24-30, (2000)
[3]  
Li S., Huang L., Nonviral gene therapy: promises and challenges, Gene Ther, 7, pp. 31-34, (2000)
[4]  
Marshall E., FDA halts all gene therapy trials at Penn [news], Science, 287, (2000)
[5]  
Hall S.J., Bar-Chama N., Ta S., Et al., Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction, Hum Gene Ther, 11, pp. 1705-1712, (2000)
[6]  
Paielli D.L., Wing M.S., Rogulski K.R., Et al., Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse, Mol Ther, 1, pp. 263-274, (2000)
[7]  
Yeung F., Li X., Ellett J., Et al., Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells, J Biol Chem, 275, pp. 40846-40855, (2000)
[8]  
Siemens D.R., Austin J.C., Hedican S.P., Et al., Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model, J Natl Cancer Inst, 92, pp. 403-412, (2000)
[9]  
Berges R.R., Furuya Y., Remington L., Et al., Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation, Proc Natl Acad Sci U S A, 90, pp. 8910-8914, (1993)
[10]  
Steiner M.S., Gingrich J.R., Gene therapy for prostate cancer: where are we now?, J Urol, 164, pp. 1121-1136, (2000)
123456